Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2026 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungenAcceptable Use
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to Reports
Fundraising

AbCellera

AbCellera Raises $555M in Series B

2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, CanadaJune 12, 20242 min read
Employees
400+

AbCellera Raises $555M in Series B


AbCellera has successfully raised $555M in a Series B at a $5.7B valuation led by Peter Thiel, Eli Lilly, Fast Forward Innovations, DCVC Bio.


Company Overview


AbCellera is a Biotech company headquartered in 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada, founded in 2012 with 400+ employees.


Antibody discovery platform


Fundraising Details


  • Amount Raised: $555M
  • Round Type: Series B
  • Valuation: $5.7B
  • Date: 2024-06-12
  • Investors: Peter Thiel, Eli Lilly, Fast Forward Innovations, DCVC Bio

About AbCellera


Antibody discovery platform The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
  • Founded: 2012
  • Team Size: 400+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in AbCellera's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. AbCellera's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $5.7B valuation marks an important milestone for AbCellera, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, AbCellera is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-06-12. For more information about AbCellera, visit their headquarters at 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.

Company Info

Headquarters
2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
Founded
2012
Team Size
400+

Topics

Fundraising(2912)Series B(306)BiotechAbCellera

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free